NCT06899802 - A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine | Biotech Hunter

Enrollment

411

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

March 31, 2027

Conditions

Encephalitis

Interventions

BIOLOGICAL

MVA-BN-WEV

MVA-mBN396 (common name MVA-BN-WEV vaccine), is a highly attenuated, live recombinant virus based on the licensed viral vector MVA-BN, provided as a liquid frozen formulation. It is administered as an intramuscular injection.

OTHER

Placebo

Tris-Buffered Saline (TBS) (placebo) is a clear liquid, free from visible extraneous particles. TBS is acceptable for use as a diluent and for intramuscular injection.

Trial Locations (9)

30047

Lifeline Primary Care, Inc. / CCT Research, Lilburn

40383

Versailles Family Medicine, PLLC/CCT Research, Versailles

64151

Clay-Platte Family Medicine, P.C./CCT Research, Kansas City

65109

Jefferson City Medical Group / Avacare, Jefferson City

66219

Johnson County Clin-Trials, Lenexa

68046

Papillion Research Center/CCT Research, Papillion

70065

Benchmark Research, Kenner

76904

Benchmark Research, San Angelo

95864

Benchmark Research, Sacramento